A Study to Evaluate Chemotherapy-Induced Nausea in Breast Cancer Patients


About this study

The purpose of the study is to alleviate the occurrence of chemotherapy-induced nausea (CIN) and to improve chemotherapy treatment outcomes. Recent research has shown that changes in the functions performed by the gut microbiome can cause the occurrence of chemotherapy-induced symptoms that include chemotherapy-induced nausea. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of Stage I-III adenocarcinoma of the breast will be recruited at Mayo Clinic, Arizona.
  • Able to read, write and understand English.
  • At least 21  years of age.
  • Chemotherapy naïveF.
  • Female gender.
  • Will receive taxotere + cyclophosphamide treatment +/- Trastuzumab.

Exclusion Criteria:​​​​​​

  • Metastatic disease.
  • Concurrent radiation therapy.
  • Concurrent antibiotic treatment.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Brenda Ernst, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions